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ABSTRACT
Objectives: Previous validation of the HIV Treatment Satis-
faction Questionnaire status version (HIVTSQs) found that
nine of the 10 items performed well, but the demands item
needed revision. This study investigated the psychometric
properties of the revised HIVTSQs and new change version
(HIVTSQc).
Methods: English-speaking Americans completed the
HIVTSQs at baseline and Week 48 of a clinical trial of HIV
treatments, and the HIVTSQc at Week 48. Demographic and
viral load information was collected. Psychometric valida-
tion used item frequency distributions, Conﬁrmatory Factor
Analysis (CFA), item-total correlations, Cronbach’s alpha,
Spearman’s rank correlation, Kruskal–Wallis and Mann–
Whitney tests.
Results: At baseline, 126 of the 152 patients completed the
HIVTSQs fully (100 of 106 at Week 48). The negatively
skewed distribution of the revised demands item resembled
that of the other nine, with comparable missing data. CFA
(baseline and Week 48) supported the general satisfaction/
clinical subscale (alpha 0.83; 0.85), lifestyle/ease subscale
including demands (alpha 0.82; 0.85), and 10-item treatment
satisfaction scale (alpha 0.89; 0.91). Subscale and scale
scores differed signiﬁcantly between ethnic groups. Viral
load was not signiﬁcantly related to subscale or scale scores.
At Week 48, 97 of 106 patients completed the HIVTSQc
fully. All items had negatively skewed distributions. CFA
supported two subscales (general satisfaction/clinical change
alpha 0.85; lifestyle/ease change alpha 0.88) and 10-item
treatment satisfaction change scale (alpha 0.92). Viral load
change between baseline and Week 48 correlated signiﬁ-
cantly with patients’ perceptions of change in HIV control
(control(c) item), but not with scale or subscale scores.
Conclusion: The excellent psychometric properties of the
HIVTSQs and HIVTSQc support their use in clinical trials.
Keywords: ethnicity, HIV, questionnaire, treatment
satisfaction.
Introduction
The HIV Treatment Satisfaction Questionnaire
(HIVTSQ) was developed to evaluate treatments for
HIV [1]. It is one of several condition-speciﬁc measures
using the format of the Diabetes Treatment Satisfac-
tion Questionnaire (DTSQ) [2,3]. Others are for end
stage renal disease [4], genital herpes [5], diabetic
retinopathy [6], hypothyroidism [7], as well as the
DTSQ-Teen for teenagers with diabetes and DTSQ-
Parent for parents of children with diabetes.
In the original validation study, 150 American and
Canadian patients completed an earlier version of the
10-item HIVTSQ status version (HIVTSQs). Psycho-
metric analyses [1] revealed two subscales (the ﬁve-
item general satisfaction/clinical subscale [range 0–30]
and the four-item lifestyle/ease subscale [range 0–24])
as well as the total treatment satisfaction scale (range
0–54), computed from nine of the 10 items. Each scale
and subscale had good internal consistency reliability.
The validation showed that the fourth item, “How
demanding is your present form of treatment (in terms
of time, effort, thought, etc.)?” was problematic. It
was the only item for which the least favorable
response (very demanding) was to the left of the scale,
scoring 6 and the most favorable response (very unde-
manding) to the right, scoring 0. For the remaining
nine items, the most favorable response was to the left.
Distributions of nine items were negatively skewed,
most patients indicating high levels of satisfaction.
Scores for the demanding item, however, formed a
more rectangular distribution, indicating that some
patients may have circled responses toward the left,
believing these to be more favorable, as for the other
nine items. Statistical analyses showed that the
demanding item did not ﬁt into the structure of the
measure. Recommendations for computing scores
therefore excluded this item. The report recommended
that the problematic item wording should be changed
to: How satisﬁed are you with the demands made by
your current treatment? (response options very satis-
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ﬁed [6] to the left, to very dissatisﬁed [0] to the right).
The earlier version of the HIVTSQs had already been
used in two further trials and translated into several
languages without involvement of its authors. For
those language versions with acceptable translations,
psychometric analyses strongly supported the nine-
item treatment satisfaction scale, which proved sensi-
tive to differences between treatment groups in three
trials [8].
A “change” version of the DTSQ (the DTSQc) has
been found valuable in overcoming ceiling effects that
often arise with status measures of satisfaction, the
DTSQs (status version) being no exception. Although
the DTSQs has proved sensitive to change in many tri-
als (reviews [2], [9]), the DTSQc enhances that sensi-
tivity by allowing those who were satisﬁed at baseline
to express even greater satisfaction at follow-up
[10,11]. An HIVTSQ new change version (HIVTSQc)
should prove similarly useful in identifying improve-
ments, particularly where ceiling effects are apparent.
Linguistically validated versions of the HIVTSQs
and the HIVTSQc (Table 1) were therefore prepared in
several languages, each with the revised demanding
item having the most favorable response to the left
(now labeled demands, Item 4 in each measure). In the
present work, we investigate the structure of the
revised HIVTSQs and the new HIVTSQc (English ver-
sion completed in the United States) and the internal
consistency reliability of any scales/subscales, to deter-
mine the scoring for each measure, including proce-
dures for dealing with missing values and the
relationship between questionnaire scores, demo-
graphic variables, and viral load.
Methods
Procedure
At baseline (Day 1) of a clinical trial of an investiga-
tional product for treatment of HIV, just before
randomization  to  one  of  three  treatments,  the
Table 1 Item content of the HIVTSQs and HIVTSQc
HIVTSQs HIVTSQc
Instructions Instructions
The following questions are 
concerned with your anti-HIV 
medicine therapy for HIV 
infection and your experience 
over the past few weeks. Please 
answer each question by circling a 
number on each of the scales.
The following questions are concerned 
with your present anti-HIV medicine 
therapy compared with your experience 
of medicine therapy used just before you 
started in the current study. We are 
interested to know how, if at all, your 
experience of medicine therapy has 
changed. Please answer each question by 
circling a number on each of the scales 
to indicate the extent to which you have 
experienced changes. If you have 
experienced no change, circle “0”.
Item
no.
Item label
[Sufﬁx (c) denotes
item label in the 
change version]
Item wording Response options 6–0 Response options 6–0
1 Current treatment How satisﬁed are you with your 
current treatment?
Very satisﬁed 6 to 0 very dissatisﬁed Much more satisﬁed now 3 to −3 much less 
satisﬁed now
2 Control How well controlled do you feel 
your HIV has been recently?
Very well controlled 6 to 0 very 
poorly controlled
Much better controlled now 3 to −3 much 
worse controlled now
3 Side effects How satisﬁed are you with any side 
effects of your present treatment?
Very satisﬁed 6 to 0 very dissatisﬁed Much more satisﬁed now 3 to −3 much less 
satisﬁed now
4 Demands How satisﬁed are you with the 
demands made by your current 
treatment?
Very satisﬁed 6 to 0 very dissatisﬁed Much more satisﬁed now 3 to −3 much less 
satisﬁed now
5 Convenience How convenient have you been 
ﬁnding your treatment to be 
recently?
Very convenient 6 to 0 very 
inconvenient
Much more convenient now 3 to −3 much 
less convenient now
6 Flexibility How ﬂexible have you been ﬁnding 
your treatment to be recently?
Very ﬂexible 6 to 0 very inﬂexible Much more ﬂexible now 3 to −3 much less 
ﬂexible now
7 Understanding How satisﬁed are you with your 
understanding of your HIV?
Very satisﬁed 6 to 0 very dissatisﬁed Much more satisﬁed now 3 to −3 much less 
satisﬁed now
8 Lifestyle How satisﬁed are you with the 
extent to which the treatment ﬁts 
in with your lifestyle?
Very satisﬁed 6 to 0 very dissatisﬁed Much more satisﬁed now 3 to −3 much less 
satisﬁed now
9 Recommend to others Would you recommend your 
present treatment to someone 
else with HIV?
Yes I would deﬁnitely recommend 
the treatment 6 to 0 No I would 
deﬁnitely not recommend the 
treatment
Much more satisﬁed now 3 to −3 much less 
satisﬁed now
10 Continue How satisﬁed would you be to 
continue with your present form 
of treatment?
Very satisﬁed 6 to 0 very dissatisﬁed Much more likely to recommend the 
treatment now 3 to −3 much less likely 
to recommend the treatment now
Please make sure that you have circled one number on each of the scales.
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HIVTSQs (English version) was administered to 152
English-speaking American, HIV-positive individuals
who had already received antiretroviral therapy. This
was a different sample from the 150 patients in the
previous validation study [1]. At screening, which pre-
ceded baseline by some weeks, patients eligible to par-
ticipate in the present trial were “experiencing failure
of their antiretroviral therapy regimen” (plasma HIV-
1 RNA ≥ 1000 copies/ml). All patients who completed
at least one HIVTSQ measure during the trial were
included, whether or not they completed the trial. The
HIVTSQc (English) was administered to the 106
patients remaining in the trial at Week 48 on rand-
omized treatment. Patients completed the measures
themselves, before seeing the clinician and before being
informed of their viral load. Demographic data includ-
ing age, gender, and ethnicity were recorded, as was
viral load at each time point.
Analysis
Demographic and disease characteristics were summa-
rized. The distribution of item scores and frequency of
missing data were examined. Week 48 HIVTSQc item
scores were correlated against the difference between
HIVTSQs item scores at baseline and Week 48 (com-
puted as Week 48—baseline). Analyses followed
broadly the same sequence for both HIVTSQs and
HIVTSQc. Conﬁrmatory Factor Analysis (CFA) was
conducted on baseline and Week 48 HIVTSQs item
scores (without and then with the demands item), and
on all 10 HIVTSQc scores, using the maximum likeli-
hood estimation algorithm of Amos 4.01, to determine
whether the general satisfaction/clinical and lifestyle/
ease subscales, then the treatment satisfaction scale,
were supported. A normed ﬁt index (NFI) ≥0.9 was
considered to indicate an acceptable ﬁt [12] and stand-
ardized regression weights >0.4 for contributing items
were considered acceptable. In SPSS for Windows 12.0
(SPSS Inc. Chicago, IL), corrected item–total correla-
tions (each item correlated with the sum of the remain-
ing items) and Cronbach’s alpha were used to
determine the internal consistency reliability of scales/
subscales identiﬁed in the CFAs. Alpha > 0.7 is usually
considered acceptable, though for some purposes,
alpha > 0.8 is desirable. Item–total correlations and
alpha with each item removed were examined to iden-
tify any items not contributing well to the scale, indi-
cated by a relatively poor item–total correlation and an
increased alpha if that item was removed.
The method for computing missing values for any
scale or subscale involved removing ﬁrst the item
whose removal caused the greatest fall in the scale
alpha. This is the “strongest” item and internal con-
sistency will be damaged most if this item is missed.
Cronbach’s alpha was then calculated without that
item. If the alpha remained above 0.7, the item whose
removal now caused the greatest fall in the scale alpha
was removed and Cronbach’s alpha calculated again
without both the strongest and second item. The proc-
ess was repeated cyclically until the scale alpha fell
below 0.7. The number of items that could be missed,
but the scale score still computed using completed
items, was the number of items remaining in the Cron-
bach’s alpha analysis before alpha fell below 0.7. The
number of items that could be missed while retaining
an alpha > 0.8 was also ascertained. In order to retain
a range of content when judging satisfaction, a maxi-
mum of half the items may be missed (e.g., ﬁve from a
10-item scale), regardless of the alpha achieved.
Scale and subscale scores were then computed and
associations with demographic characteristics (age at
recruitment, sex, and ethnicity) and viral load at that
visit were examined. Nonparametric statistics were
used to determine whether there were signiﬁcant
demographic differences: Mann–Whitney U-tests
compared the two age categories (median split into
younger <40 years and older ≥40 years) and the two
sexes; Kruskal–Wallis multiple comparison test,
backed by Mann–Whitney U-tests, compared the three
ethnic groups (Hispanic, African American, and Cau-
casian). In each case, a probability (P) of <0.05 (two-
tailed) indicated a signiﬁcant difference between
subgroups. Subscale and scale scores and control item
scores were correlated against viral load (Spearman’s
rank correlation). In the case of the HIVTSQs, this was
viral load at baseline and again at Week 48; in the case
of HIVTSQc, it was change in viral load between base-
line and Week 48, computed as (Week 48—baseline)
so that a more negative score represented a greater
decrease in viral load during the trial (improved HIV
control)).
Results
HIVTSQs Validation
Demographic  and  disease  characteristics. Table 2
describes the HIVTSQs baseline sample. The majority
was men and the average age was around 40 years.
Just over half were Caucasian and 37.5% were African
American. Viral load varied considerably, shown by
the minimum and maximum values and the fact that
the standard deviation exceeded the mean. The viral
load distribution was positively skewed, 51.1% with
viral load <11,000 and only 7.1% with viral load
>200,000. HIV-1 RNA (log10) is also shown. Although
all were immunologically compromised when screened
for trial participation (HIV-1 RNA ≥ 1000 copies/ml),
12 had viral loads <1000 and three had viral loads
<400 HIV-1 RNA copies/ml at baseline. One scored
the lowest possible on the assay (<50, coded as 49).
Distribution  of  HIVTSQs  item  scores. Scores for
every HIVTSQs item, including demands, had a nega-
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tively skewed distribution, with a greater frequency of
responses toward the higher end of the 0–6 scale, indi-
cating generally high satisfaction. Baseline satisfaction
scores did, however, include some toward the center
and lower end of the scale, as expected for people
experiencing failure of antiretroviral therapy. Control
item scores most approximated a normal distribution
(mode = 4). For the remaining items, the modal score
was higher (mode = 5 for items 4, 5, 6, and 8;
mode = 6 for items 1, 3, 7, 9, and 10).
HIVTSQs missing values. If any item is missed more
than the others, the wording may be problematic or
the content is irrelevant to the patient population. A
total of 126 people (82.9%) completed the HIVTSQs
in full at baseline. Although 10 missed the HIVTSQs
entirely, it is not known whether they were given it to
complete. A further 16 missed some items, but not oth-
ers (between one and eight items missed), and so had
clearly been given the HIVTSQs to complete. The
items they missed were examined to determine
whether the revised demands item was missed any
more frequently than other items. The number to miss
each item ranged between two (lifestyle) and nine
(understanding). Only four missed demands. Demo-
graphic characteristics of those who missed items were
examined. Only 77.2% of African American people
completed the HIVTSQs fully, compared with 85.7%
Hispanic and 86.3% Caucasian people. Those missing
all 10 items were similar demographically to the entire
sample: nine men and one woman; seven Caucasian,
two African American, and one Hispanic; mean age
44.5 (SD 6.3). Of the 16 who completed some items
but not others, however, 11 were African American
and only four were Caucasian. All those missing six or
more items were African American. Considering the
142 who attempted the HIVTSQs, 69 of the 73 Cau-
casian patients, 12 of the 13 Hispanic patients, and the
“other” man completed it fully, but only 44 of 55 Afri-
can American patients. A chi-square test (three ethnic
groups [excluding the “other” man] and two comple-
tion categories [full vs. partial completion]) revealed a
signiﬁcant ethnic difference in completion (χ2 = 6.76;
n = 141; df = 2; P = 0.03).
HIVTSQs structure
Baseline structure. The hypothesized structure found
in the original validation [1], with items 1, 2, 3, 9, and
10 loading on one factor (general satisfaction/clinical),
and items 5 to 8 loading on the other (lifestyle/ease),
was tested, allowing for correlation between the two
latent variables, using the maximum likelihood estima-
tion algorithm in Amos. The ﬁt of the model was good:
χ2 for the solution was 56.81 (df = 26; P < 0.001), χ2/
df = 2.19, and NFI = 0.98, which exceeds the required
value of 0.9 for goodness of ﬁt. The two latent varia-
bles correlated 0.69. When the demands item was
added (hypothesized as ﬁtting into the lifestyle/ease
subscale), χ2 was 116.67 (df = 34; P < 0.001), χ2/
df = 3.43, and NFI = 0.97. The two latent variables
correlated 0.76. In both the nine-item and 10-item
analysis, nine items had standardized regression
weights >0.4, but the weight for understanding was
slightly lower. Thus, the ﬁt to the model with two ﬁve-
item subscales (general satisfaction/clinical and life-
style/ease) was acceptable, but understanding did not
ﬁt as well as the other items. When the goodness of ﬁt
of a single nine-item scale model (without demands)
Table 2 Demographic characteristics, treatment group, and viral load of patients included in baseline analysis of HIVTSQs data and
Week 48 analysis of HIVTSQs and HIVTSQc data
Characteristic
Baseline sample Week 48 sample 
n
Frequency
(% of sample) Mean (SD)
Median 
(min-max) n
Frequency
(% of sample) Mean (SD)
Median 
(min-max)
Age (years) 152 — 41.2 (7.9) 40 (24–69) 106 — 42.1 (7.8) 41 (27–67)
Sex 152 106
Men 129 (84.9) 93 (87.7)
Women 23 (15.1) 13 (12.3)
Ethnicity 152
Hispanic 14 (9.2) 9 (8.5)
African American 57 (37.5) 39 (36.8)
Caucasian 80 (52.6) 57 (53.8)
Other 1 (0.7) 1 (0.9)
Allocated to treatment group 152 106
Group 1 55 (36.2) 34 (32.1)
Group 2 47 (30.9) 34 (32.1)
Group 3 50 (32.9) 38 (35.8)
Viral load
(HIV-1 RNA copies/ml) 141 56,023.1
(115,960.7)
10,915
(49–606,043)
105 21,181.7
(90,724.8)
49
(49–671,220)
<1000 12 (8.5) 83 (79.0)
≥1000 129 (91.5) 22 (21.0)
HIV-1 RNA copies/ml(log10) 141 4.09 (0.82) 4.04 (1.69–5.78) 105 2.34 (1.10) 1.69 (1.69–5.83)
HIVTSQc, HIV Treatment Satisfaction Questionnaire new change version; HIVTSQs, HIV Treatment Satisfaction Questionnaire status version.
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was tested, χ2 was 116.73 (df = 27; P < 0.001), χ2/
df = 4.32, and NFI = 0.96. Adding in the demands
item, χ2 was 167.37 (df = 35; P < 0.001), χ2/df = 4.78,
and NFI = 0.95. In both cases, the standardized regres-
sion weight for understanding fell just below 0.4, but
the weight for demands was strong (0.85) (see Table 3
summarizing the 10-item CFAs).
Week 48 structure. In order to check this structure
among the same participants but with experience of
different trial treatments, CFA was performed on data
collected in Week 48 for all patients completing the
trial on randomized treatment, even though some
changed their background therapy for reasons of safety
or intolerance. Because the three treatment groups had
different treatment experiences, the following check
was conducted to determine whether their HIVTSQs
scores could be combined for psychometric analysis: 1)
the raw scores for the 10 items were subjected to
Principal Components Analysis (PCA), with a forced
single-factor solution; 2) within each of the three
treatment groups separately, normalized scores (z-
scores) were computed for each questionnaire item; 3)
combining the data set again, these z-scores were sub-
jected to PCA, with a forced single-factor solution; and
4) the 10 factor loadings for 1) were regressed against
those from 3) (n = 10). If the regression coefﬁcient is
close to 1 and the constant close to zero, then the three
subsets of data can be combined. The correlation
between the two sets of loadings was very high
(R = 0.994), the constant (−0.050) was not signiﬁ-
cantly different from zero (t[8] = 1.57; P > 0.05) and
the slope (1.061) was not signiﬁcantly different from 1
(t[8] = 1.419; P > 0.05). This indicated that even
though the absolute values in each treatment group
might differ, the interrelationships between items are
similar and the three groups can be combined for fur-
ther analysis. All 10 HIVTSQs items (Week 48) were
entered into a CFA, to determine goodness of ﬁt of the
two-subscale model. χ2 was 83.23 (df = 34; P < 0.001),
χ2/df = 2.45, and NFI = 0.98, with the two latent var-
iables correlating 0.83. All 10 items had standardized
regression weights >0.4, though understanding was the
weakest at 0.41. Testing the goodness of ﬁt of a 10-item
single-scale model (Week 48), χ2 was 137.95 (df = 35;
P < 0.001), χ2/df = 3.94, and NFI = 0.97. Nine items
had standardized regression weights >0.4, though
understanding was exactly 0.4 (Table 3).
Internal consistency reliability of two subscales and
single scale. Internal consistency reliability analysis
was conducted ﬁrst on baseline data. Table 4  provides
the corrected item–total correlation for each item and
alpha with each item removed (n = 129 who com-
pleted all ﬁve general satisfaction/clinical subscale
items, n = 128 for the ﬁve lifestyle/ease items, and
n = 126 for the 10 treatment satisfaction scale items).
The scale alpha for general satisfaction/clinical was
0.83, for lifestyle/ease was 0.82, and for treatment sat-
isfaction was 0.89. In each case, all item–total corre-
lations were >0.4. As expected from the CFA, the
weakest item was understanding in the general satis-
faction/clinical subscale and treatment satisfaction
scale. Alpha > 0.8 conﬁrmed very good internal con-
sistency reliability at Week 48 (general satisfaction/
clinical alpha = 0.85, lifestyle/ease alpha = 0.85, and
treatment satisfaction alpha = 0.91). We conclude
from these analyses that the general satisfaction/clini-
cal subscale can be computed from items 1, 2, 3, 9, and
10 and the lifestyle/ease subscale from items 4 to 8
(possible range 0–30 for each subscale) and treatment
satisfaction scale score can be computed as the sum of
all 10 HIVTSQs items (possible range 0–60), but that
understanding is a relatively weak item.
Dealing with missing HIVTSQs values. Items were
removed cumulatively and alpha was calculated again
for each subscale and scale at baseline. Their removal
Table 3 Conﬁrmatory Factor Analysis of the 10 HIVTSQs items (at baseline and Week 48, showing standardized regression weights
for each variable and NFI for the model)
Item
Baseline Week 48
Two latent variables Single latent variable Two latent variables Single latent variable
General satisfaction/
clinical subscale
Lifestyle/ease
subscale
Total treatment
satisfaction scale
General satisfaction/
clinical subscale
Lifestyle/ease
subscale
Total treatment
satisfaction scale
NFI = 0.97 NFI = 0.95 NFI = 0.98 NFI = 0.97
1. Current treatment 0.846 0.725 0.914 0.798
2. Control 0.767 0.671 0.767 0.665
3. Side effects 0.514 0.595 0.800 0.693
4. Demands 0.853 0.861 0.879 0.876
5. Convenience 0.894 0.812 0.950 0.923
6. Flexibility 0.654 0.632 0.669 0.675
7. Understanding 0.378 0.368 0.409 0.400
8. Lifestyle 0.720 0.661 0.882 0.859
9. Recommend to others 0.634 0.693 0.693 0.705
10. Continue 0.820 0.698 0.742 0.734
HIVTSQs, HIV Treatment Satisfaction Questionnaire status version; NFI, normed ﬁt index.
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was not in the exact order expected from the original
alpha-if-item-deleted values. For example, item 1 was
removed from the treatment satisfaction scale before
item 5. This is because the number of participants con-
tributing to the analysis increased and the content of
the scale changed with cumulative removal of items.
Removing the strongest item (current treatment) from
the general satisfaction/clinical subscale resulted in a
fall to alpha = 0.767, but removal of the second
strongest (continue) would result in a fall to 0.681, so
only one general satisfaction/clinical item can be
missed and substituted for with the mean of the
remaining four items before the general satisfaction/
clinical subscale is computed as the sum of the ﬁve
items. Removing the strongest item (convenience) from
the lifestyle/ease subscale resulted in a fall to
alpha = 0.742, but removal of the second strongest
(lifestyle) would result in a fall to 0.606, so only one
lifestyle/ease item can be missed and substituted by the
mean of the remaining four items before the lifestyle/
ease subscale is computed as the sum of the ﬁve items.
Each subscale cannot be computed for those missing
more than one contributing item. If greater internal
consistency reliability of >0.8 is needed, then no miss-
ing values can be tolerated. Removal of the strongest
item from the total treatment satisfaction scale
(demands) reduced alpha to 0.868. Removal also of
current treatment reduced alpha to 0.847, then addi-
tional removal of convenience reduced alpha to 0.819.
Thus, three items may be missed before alpha falls
below 0.8. Further removal of recommend to others
reduced alpha to 0.778 and removal of control
reduced alpha further to 0.723. Removal of under-
standing would reduce the scale alpha to 0.705, which
just exceeds the criterion level of alpha > 0.7. Never-
theless, in order to retain the range of content of the
measure when computing missing values, a maximum
of ﬁve items (half the scale) may be missed and each
computed as the mean of completed item scores. The
treatment satisfaction scale score can now be com-
puted as the sum of the 10 item scores, including sub-
stituted means as necessary for up to ﬁve items (for
alpha > 0.7) or three items (for alpha > 0.8). If six or
more items are missed, the scale score should not be
computed.
Computing two subscale and scale scores. Using the
method of computing subscales scores, in which only
one missing value is replaced by the mean, 136 general
satisfaction/clinical subscale scores were computed at
baseline (an additional seven, compared with the 129
completing all ﬁve items). Mean general satisfaction/
clinical was 20.6 (SD 6.7), median and mode 22, rang-
ing from 2 to 30, and skewness −0.53 (SE 0.21). Using
the same method for the lifestyle/ease subscale, 137
scores could be computed (compared with 128 com-
pleting all ﬁve items). Mean lifestyle/ease was 22.9 (SD
5.6), median and mode 24, ranging from 1 to 30.
Thus, both subscales provide a range of scores, with a
negative skew, the median being greater than the
mean. Using the method of computing missing values
in which up to ﬁve missing values can be replaced by
the mean, baseline treatment satisfaction scores were
computed for 139 patients, an additional 13 (eight
African American, four Caucasian, and one Hispanic)
compared with the 126 who completed the HIVTSQs
fully. Mean treatment satisfaction was 43.5 (SD 11.3);
median 45 (ranging 5–60). The mode was 50 (10
below the maximum possible) and skewness −0.66 (SE
0.21).
Examination of subscale and scale scores in relation to
demographic variables and viral load. There was no
signiﬁcant difference between the two age categories or
between sexes in general satisfaction/clinical, lifestyle/
ease or treatment satisfaction, but there was a differ-
ence (Kruskal–Wallis) between ethnic groups for all
three scores (Table 5). At baseline, African American
people reported signiﬁcantly higher general satisfac-
tion/clinical than did Caucasian people (Mann–Whit-
ney P = 0.034), higher lifestyle/ease (P = 0.011), and
higher treatment satisfaction (P = 0.007). The direc-
Table 4 Internal consistency reliability of HIVTSQs subscales and scale (at baseline)
Item
General satisfaction/clinical subscale
Scale alpha = 0.831
Lifestyle/ease subscale
Scale alpha = 0.821
Treatment satisfaction scale
Scale alpha = 0.891 
Corrected item–
total correlation
Cronbach’s alpha
if item deleted
Corrected item–
total correlation
Cronbach’s alpha
if item deleted
Corrected item–
total correlation
Cronbach’s alpha
if item deleted
1. Current treatment 0.74 0.767 0.68 0.876
2. Control 0.67 0.788 0.67 0.877
3. Side effects 0.46 0.845 0.54 0.887
4. Demands 0.66 0.775 0.79 0.868
5. Convenience 0.77 0.742 0.73 0.876
6. Flexibility 0.55 0.812 0.56 0.885
7. Understanding 0.43 0.834 0.40 0.893
8. Lifestyle 0.71 0.758 0.66 0.878
9. Recommend to others 0.60 0.806 0.69 0.876
10. Continue 0.71 0.774 0.65 0.879
HIVTSQs, HIV Treatment Satisfaction Questionnaire status version.
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tion of the difference is all the more striking when
baseline viral load is examined. Although there was no
signiﬁcant difference between viral loads of the three
ethnic groups (F = 1.82; df = 2; P = 0.17), the mean
viral load for Caucasian patients was 38,540.6 HIV-1
RNA copies/ml (SD 91,958.1), whereas for African
American patients, it was higher at 77,868.1 (SD
144,729.2), the Hispanic patients having an interme-
diate mean 62,215.4 (SD 97,768.7). African Ameri-
cans thus had poorer HIV control, yet greater
satisfaction.
Baseline viral load was correlated against control
item scores (r = −0.14; n = 138; P = 0.09), against gen-
eral satisfaction/clinical (r = −0.12; n = 135; P = 0.16),
lifestyle/ease (r = −0.003; n = 136; P = 0.98), and
treatment satisfaction (r = −0.09; n = 138; P = 0.60).
None were signiﬁcant. At Week 48, however, the cor-
relation with viral load was signiﬁcant for the control
item (r = −0.44; n = 102; P < 0.001) and for general
satisfaction/clinical (r = −0.24; n = 101; P = 0.018),
while remaining nonsigniﬁcant for lifestyle/ease
(r = 0.001; n = 102; P = 0.99) and treatment satisfac-
tion (r = −0.10; n = 102; P = 0.30). Investigation of
baseline correlations with viral load for each ethnic
group (Hispanic, African American, and Caucasian)
revealed a signiﬁcant correlation between viral load
and the control item for Caucasian patients (r = −0.23;
n = 73; P = 0.046), but this was weaker for African
Americans (r = −0.17; n = 51; P = 0.22) and negligible
for Hispanic patients (r = 0.08; n = 13; P = 0.80). At
Week 48, the correlation was more strongly signiﬁcant
for Caucasian patients (r = −0.42; n = 56; P = 0.001),
signiﬁcant for African American patients (r = −0.48;
n = 36; P = 0.003) and followed the same pattern,
albeit less strongly, for the much smaller sample of
Hispanic patients (r = −0.13; n = 9; P = 0.74). The
negative correlation between viral load and general
satisfaction/clinical scores was stronger at Week 48 for
Table 5 HIVTSQs subscale and scale scores of demographic subgroups (at baseline)
Characteristic*
Subgroups of patients compared 
HIVTSQs subscale/scale score with Mean (SD) Median (min-max) Signiﬁcance
General satisfaction/clinical subscale
Age category Younger (n = 66) Older (n = 70) P = 0.33
Mean 20.1 (6.8) Mean 21.2 (6.7)
Median 21(2–30) Median 22 (4–30)
Sex Men (n = 116) Women (n = 20) P = 0.29
Mean 20.4 (6.7) Mean 22.0 (6.7)
Median 21.5 (2–30) Median 22.3 (4–30)
Ethnicity† Hispanic (n = 13) African American (n = 50) Caucasian (n = 72) P = 0.03
Mean 22.5 (6.5) Mean 22.0 (6.9) Mean 19.4 (6.5)
Median 23 (10–29) Median 23 (4–30) Median 20.5 (2–30)
Hispanic African American P = 0.98
Hispanic
African American
Caucasian
Caucasian
P = 0.09
P = 0.02
Lifestyle/ease subscale
Age category Younger (n = 66) Older (n = 71) P = 0.71
Mean 23.1 (5.4) Mean 22.6 (5.8)
Median 24 (8–30) Median 24 (1–30)
Sex Men (n = 117) Women (n = 20) P = 0.33
Mean 23.1 (5.4) Mean 21.6 (6.8)
Median 24 (8–30) Median 23.0 (1–29)
Ethnicity† Hispanic (n = 13) African American (n = 50) Caucasian (n = 73) P = 0.01
Mean 24.4 (6.1) Mean 24.1 (5.6) Mean 21.9 (5.3)
Median 27 (11.25–30) Median 25 (1–30) Median 23 (8–30)
Hispanic African American P = 0.53
Hispanic
African American
Caucasian
Caucasian
P = 0.08
P = 0.006
Treatment satisfaction scale
Age category Younger (n = 68) Older (n = 71) P = 0.64
Mean 43.2 (10.8) Mean 43.7 (11.76)
Median 11.0 (17–60) Median 16.0 (5–60)
Sex Men (n = 119) Women (n = 20) P = 0.86
Mean 43.4 (11.1) Mean 43.6 (12.4)
Median 45.0 (16–60) Median 44.5 (5–58.9)
Ethnicity† Hispanic (n = 13) African American (n = 52) Caucasian (n = 73) P = 0.014
Mean 47.0 (11.0) Mean 46.0 (11.53) Mean 41.2 (10.7)
Median 52.0 (27–58) Median 47.5 (5–60) Median 43.0 (17–60)
Hispanic African American P = 0.90
Hispanic
African American
Caucasian
Caucasian
P = 0.07
P = 0.007
*Mann–Whitney to compare two age categories (with median split at 40 years) and to compare men and women. Kruskal–Wallis (with χ2) to compare three ethic groups, fol-
lowed by Mann–Whitney between pairs of ethnic group.
†Other ethnicity (n = 1) not included in analyses because of insufﬁcient number of cases.
n indicates number in subgroup.
HIVTSQs, HIV Treatment Satisfaction Questionnaire status version.
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African Americans (r = −0.34; n = 35; P = 0.048) and
for Caucasian patients (r = −0.17; n = 56; P = 0.20)
than it had been at baseline (African American [r =
−0.21; n = 49; P = 0.14]; Caucasian [r = −0.10; n = 72;
P = 0.38]), indicating a stronger relationship between
patient perceptions of the clinical effectiveness of their
treatment and test results as the trial progressed.
HIVTSQc Validation
The analyses below used HIVTSQc data collected at
Week 48 from patients completing the trial on their
randomized treatment.
Demographic and disease characteristics. By Week
48, 45 patients had withdrawn, leaving 107. Never-
theless, a Hispanic man completed the English
HIVTSQs at baseline, but US Spanish versions of
HIVTSQs and HIVTSQc thereafter, and he is therefore
excluded from Week 48 HIVTSQc analysis, leaving
n = 106 (Table 2). When recruited, the subset of the
sample providing HIVTSQc data were about a year
older than were the larger HIVTSQs baseline sample,
indicating that younger people may have withdrawn
early from the trial. Ethnic groups were in similar pro-
portions to the HIVTSQs baseline sample. At Week 48,
average viral load was lower than in the baseline anal-
ysis: 57 patients (54.3% of 105 with viral load results)
had the minimum level detected by the assay (coded as
49 HIV-1 RNA copies/ml), compared with only one
person at baseline; furthermore, 83 of 105 (79%) had
a viral load <1000, compared with 12 at baseline.
Distribution of HIVTSQc item scores. Distribution
of scores for the 10 HIVTSQc items was examined
within each of the three treatment groups. The distri-
bution for all 10 items was negatively skewed, with a
modal response of +3 for almost all items, indicating
the maximum possible degree of improvement (e.g.,
much more satisﬁed now). The only exceptions were
the mode of +2 for side effects(c) in treatment groups
1 and 3, mode of +2 for understanding(c) and joint
modal score of 2 and 3 for lifestyle(c) in treatment
group 1. The minimum score for control(c) was zero
for all three treatment groups, indicating that all
patients thought their HIV control was either as good
as that before the trial, or better. Nevertheless, for each
of the other nine items, a few patients indicated a neg-
ative change. For demands(c), ﬂexibility(c), lifestyle(c),
and recommend to others(c), there were negative
changes for at least one person in each treatment
group, indicating a belief that the trial treatment was
less satisfactory than their previous treatment. Spear-
man’s correlation between Week 48 change item scores
and the difference between status scores obtained at
baseline and Week 48 were all positive (ranging
between r = +0.12 and r = +0.39). Five correlations
were signiﬁcant (P < 0.05), indicating that change
judgments related to differences in absolute judgments
of satisfaction, though not very strongly.
HIVTSQc missing values. Of the 106 who attended
at Week 48, only nine missed any HIVTSQc items, of
whom two missed the entire measure. It is not certain
that those two were given the HIVTSQc to complete.
Nevertheless, the seven people missing 1 to 9 items
clearly had received the measure and each item was
missed by two to four of these people. Thus, no item
was missed any more frequently than another. While
56 (98.2%) Caucasian patients and the “other” eth-
nicity patient completed the measure fully, only eight
(88.9%) Hispanic and 32 (82.1%) African American
patients did so.
HIVTSQc  structure. Because the three treatment
groups had different treatment experiences, the raw-
score z-score check was conducted to determine
whether their HIVTSQc scores could be combined for
psychometric analysis, as described above for the
Week 48 HIVTSQs data. The correlation between
the two sets of loadings was very high (R = 0.995),
the constant (−0.041) was not signiﬁcantly different
from zero (t[8] = 1.530; P > 0.05), and the slope
(0.950) was not signiﬁcantly different from 1 (t[8] =
−1.429; P > 0.05). This indicated that even though
the absolute values in each group might differ, the
interrelationships between the items are similar and
the three treatment groups can be combined for fur-
ther analysis.
Conﬁrmatory Factor Analysis ﬁrst sought to con-
ﬁrm the two-subscale model, by including all 10 item
scores in the analysis, with intercorrelation between
the two latent variables. Each HIVTSQc change item
was allocated to the same subscale as for the status ver-
sion. χ2 was 193.60 (df = 34; P < 0.001), χ2/df = 5.69,
NFI = 0.92, and the two latent variables correlated
0.85. For a single 10-item treatment satisfaction
change scale (all items loading onto one latent varia-
ble), χ2 was 257.03 (df = 35; P < 0.001), χ2/df = 7.34,
and NFI = 0.90, which is just acceptable. For both the
two-subscale and single-scale model, all 10 standard-
ized regression weights were >0.4 (Table 6).
Internal consistency reliability of the treatment
satisfaction  change  scale. The internal consistency
reliability of each of the ﬁve-item subscales (general
satisfaction/clinical change and lifestyle/ease change)
and the 10-item treatment satisfaction change scale
was tested, using corrected item–total correlations and
Cronbach’s alpha statistics. Table 7  provides the item–
total correlation for each item and alpha if each item is
removed (n = 98 for each of the two subscales and
n = 97 for the treatment satisfaction change scale, hav-
ing completed all HIVTSQc items within the relevant
scale/subscale at Week 48). The scale alpha for general
Woodcock and Bradley328
satisfaction/clinical change was 0.85, the strongest
item being continue(c); for lifestyle/ease change, alpha
was 0.88, the strongest item being lifestyle(c); and
for treatment satisfaction change, alpha was 0.92,
the strongest item again being continue(c). The
demands(c) item ﬁtted well into both the lifestyle/ease
change subscale and the total treatment satisfaction
change scale. The items least integral to the treatment
satisfaction change scale were control(c) and under-
standing(c). Alpha increased when control(c) was
removed from the general satisfaction/clinical change
subscale and when understanding(c) was removed
from the lifestyle/ease change subscale. The general
satisfaction/clinical change subscale can be computed
as the sum of change items 1, 2, 3, 9, and 10, the life-
style/ease change subscale computed as the sum of
change items 4 to 8 (possible range: −15 to +15), and
the treatment satisfaction change score computed as
the sum of all 10 HIVTSQc items (possible range: +30
to −30). The higher the positive score, the greater is the
improvement in satisfaction since the start of the trial.
The more negative the score, the greater is the deteri-
oration in satisfaction.
Dealing with missing HIVTSQc values. In the gen-
eral satisfaction/clinical change subscale, removal of
the strongest item (continue(c)) caused alpha to fall to
0.768, but removal also of current treatment(c) would
cause too great a fall to 0.548. In the lifestyle/ease
change subscale, removal of the strongest item, life-
style(c), caused alpha to fall to 0.824, but removal then
of item 6 (ﬂexibility(c)) caused a fall to 0.696 (just
below the 0.7 desired minimum). Therefore, only one
item may be missed from each of the subscales and
substituted by the mean of the four remaining items
before summing all ﬁve to produce the relevant sub-
scale score. Subscale scores cannot be computed for
those missing more than one item from the subscale
concerned. To retain an alpha >0.8, no missing items
can be tolerated in either subscale. Removal of the
strongest item from the treatment satisfaction change
scale, lifestyle(c), reduced alpha to 0.897. The addi-
tional removal of continue(c) reduced it to 0.862,
removal also of ﬂexibility(c) reduced it to 0.829, and
removal also of current treatment(c) reduced it to
0.801 (still above the higher criterion of 0.8). Removal
of demands(c) reduced it considerably to 0.718.
Table 6 Conﬁrmatory Factor Analysis of the 10 HIVTSQc items (at Week 48, showing standardized regression weights for each var-
iable and NFI for the model)
Item
Two latent variables Single latent variable 
General satisfaction/
clinical change 
subscale
Lifestyle/ease 
change 
subscale
Treatment
satisfaction change
scale 
NFI = 0.90NFI = 0.92
1. Current treatment(c) 0.863 0.815
2. Control(c) 0.403 0.437
3. Side effects(c) 0.611 0.649
4. Demands(c) 0.832 0.841
5. Convenience(c) 0.821 0.761
6. Flexibility(c) 0.819 0.795
7. Understanding(c) 0.478 0.480
8. Lifestyle(c) 0.951 0.912
9. Recommend to others(c) 0.759 0.686
10. Continue(c) 0.981 0.903
HIVTSQc, HIV Treatment Satisfaction Questionnaire change version; NFI, normed ﬁt index.
Table 7 Internal consistency reliability of the HIVTSQc subscales and scale (at Week 48)
Item
General satisfaction/
clinical change subscale
Scale alpha = 0.850
Lifestyle/ease 
change subscale
Scale alpha = 0.882
Treatment satisfaction 
change scale 
Scale alpha = 0.916
Corrected item–
total correlation
Cronbach’s alpha
if item deleted
Corrected item–
total correlation
Cronbach’s alpha
if item deleted
Corrected item–
total correlation
Cronbach’s alpha
if item deleted
1. Current treatment(c) 0.83 0.78 0.77 0.903
2. Control(c) 0.40 0.88 0.38 0.921
3. Side effects(c) 0.59 0.84 0.59 0.912
4. Demands(c) 0.73 0.859 0.79 0.903
5. Convenience(c) 0.74 0.852 0.69 0.907
6. Flexibility(c) 0.82 0.830 0.77 0.903
7. Understanding(c) 0.50 0.904 0.52 0.917
8. Lifestyle(c) 0.84 0.824 0.84 0.897
9. Recommend to others(c) 0.67 0.92 0.71 0.906
10. Continue(c) 0.84 0.77 0.84 0.898
HIVTSQc, HIV Treatment Satisfaction Questionnaire change version.
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Removal of understanding(c) would reduce it to 0.707,
still above the criterion level of 0.7. Nevertheless, in
order to retain the range of content, only ﬁve items
may be missed and each can be substituted by the
mean of completed items (maximum of four items to
retain alpha > 0.8). The treatment satisfaction change
score can then be computed as the sum of the 10 item
scores, using substituted means where necessary. If six
or more items are missed, the scale score cannot be
computed.
Computing subscale and scale change scores. Week
48 general satisfaction/clinical change and lifestyle/
ease change scores were computed, using the method
of substituting up to one missing value. For general
satisfaction/clinical change, 99 scores were computed
(one more than the 98 completing all ﬁve items). Mean
general satisfaction/clinical change was 11.5 (SD 4.3),
median 13, ranging from −5.0 to +15.0; mode +15 (the
maximum possible positive change) and skewness
−2.26 (SE 0.24). For lifestyle/ease change, 100 scores
were computed (two more than the 98 completing all
ﬁve items). Mean lifestyle/ease change was 10.8 (SD
4.8), median 12, ranging from −6.0 to +15.0; mode
+15 (the greatest possible positive change) and skew-
ness −1.56 (SE 0.24). Treatment satisfaction change
scores, using the method of substituting up to a max-
imum of ﬁve missing values, could be computed for
100 patients (the 97 who completed the HIVTSQc in
full, and the additional three who missed either one or
two items). The mean treatment satisfaction change
score was 22.6 (SD 8.6); median 26.0 (ranging from
−8.3 to +30). The distribution was negatively skewed
(skewness −1.88 [SE 0.2]) with a mode of +30 (the
maximum possible positive change). Thus, both sub-
scale and scale scores were skewed considerably.
Examination of subscale and scale change scores in
relation to demographic variables and viral load.
There were no signiﬁcant age, sex or ethnic differences
in HIVTSQc general satisfaction/clinical change, life-
style/ease change or treatment satisfaction change
scores (Table 8). The correlation between change in
viral load from baseline to Week 48 and control(c)
item scores was small but signiﬁcant (r = −0.23;
n = 93; P = 0.03). The correlations between change in
viral load from baseline to Week 48 and the Week 48
HIVTSQc subscale/scale scores were, however, negli-
gible (general satisfaction/clinical change [r = −0.08;
n = 92; P = 0.48], lifestyle/ease change [r = −0.02;
n = 93; P = 0.84], and treatment satisfaction change
[r = −0.03; n = 93; P = 0.75]). Correlations were
Table 8 HIVTSQc treatment satisfaction change scores of demographic subgroups (week 48)
Characteristic*
Subgroups of patients compared, with number in subgroup (n) 
HIVTSQc subscale/scale score 
Mean (SD) and Median (min to max) Signiﬁcance
General satisfaction/clinical change subscale
Age category Younger (n = 40) Older (n = 59) P = 0.44
Mean 12.8 (2.3) Mean 11.2 (5.2)
Median 14 (6 to 15) Median 13 (−5 to 15)
Sex Men (n = 88) Women (n = 11) P = 0.41
Mean 11.7 (4.5) Mean 13.3 (1.8)
Median 13 (−5 to 15) Median 14 (10 to 15)
Ethnicity† Hispanic (n = 9) African American (n = 33) Caucasian (n = 56) P = 0.56
Mean 9.9 (7.8) Mean 12.3 (4.0) Mean 11.9 (3.7)
Median 14 (−5 to 15) Median 14 (−4 to 15) Median 13 (−3 to 15)
Lifestyle/ease change subscale
Age category Younger (n = 40) Older (n = 60) P = 0.51
Mean 10.7 (4.4) Mean 10.9 (5.1)
Median 11 (−6 to 15) Median 13 (−4 to 15)
Sex Men (n = 89) Women (n = 11) P = 0.56
Mean 10.7 (4.9) Mean 11.5 (4.1)
Median 12 (−6 to 15) Median 13.8 (4 to 15)
Ethnicity† Hispanic (n = 9) African American (n = 34) Caucasian (n = 56) P = 0.22
Mean 10.1 (6.3) Mean 11.8 (4.6) Mean 10.4 (4.6)
Median 14 (−2.5 to 15) Median 14 (−4 to 15) Median 11 (−6 to 15)
Treatment satisfaction change scale
Age category Younger (n = 40) Older (n = 60) P = 0.81
Mean 23.5 (5.9) Mean 22.0 (10.0)
Median 24 (6 to 30) Median 26 (−8.26 to 30)
Sex Men (n = 89) Women (n = 11) P = 0.47
Mean 22.3 (8.9) Mean 24.8 (5.4)
Median 26 (−8.26 to 30) Median 27.8 (17 to 30)
Ethnicity† Hispanic (n = 9) African American (n = 34) Caucasian (n = 56) P = 0.25
Mean 19.9 (14.4) Mean 24.0 (8.3) Mean 22.3 (7.6)
Median 27 (−8.26 to 30) Median 27.9 (−8 to 30) Median 23.5 (−3 to 30)
*Mann–Whitney to compare two age categories (with median split at 40 years) and to compare men and women. Kruskal–Wallis (with χ2) to compare three ethnic groups.
†Other ethnicity (n = 1) not included in analyses because of insufﬁcient number of cases. Post hoc Mann–Whitney not conducted if Kruskal–Wallis not signiﬁcant.
HIVTSQc, HIV Treatment Satisfaction Questionnaire change version.
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conducted within each ethnic group between viral load
change on the one hand and the control(c) item and
subscale and scale scores on the other. The strength of
association between control(c) and viral load change
again differed between ethnic groups. It was signiﬁcant
among Caucasian (r = −0.37; n = 51; P = 0.007) but
not African American patients (r = −0.18; n = 32;
P = 0.33). Among Hispanic patients, there was no
association (r = 0.01; n = 9; P = 0.98). None of the
correlations between viral load change and the scale
and subscale scores were signiﬁcant.
Discussion
The modiﬁcation to the HIVTSQs has meant that a 10-
item treatment satisfaction scale score with very good
internal consistency reliability can be computed,
including an important item concerning the demands
of treatment. In addition, the two subscales, measuring
general satisfaction/clinical aspects of treatment and
satisfaction with lifestyle/ease of taking the treatment
can also be computed, the latter including the new
demands item. The new HIVTSQc also has a two-
subscale structure, producing the general satisfaction/
clinical change and lifestyle/ease change subscales, as
well as a single-scale structure, producing the treatment
satisfaction change score. All have excellent internal
consistency reliability. For each measure, the subscale
scores are each computed from ﬁve items and the scale
score as the sum of all 10 items, rendering trial analysis
and interpretation of results straightforward.
The modiﬁed wording of the HIVTSQs demands
item appears to have solved the problem identiﬁed
with the earlier version. Now, all items have a similar,
negatively skewed distribution. The control item
approximated more closely a normal distribution at
baseline, perhaps because patients were recruited as
experiencing compromised immunity on pretrial med-
ication. The previous study by Woodcock and Bradley
[1] found the HIVTSQs to be acceptable to patients
who had been taking randomized medication for 8 or
16 weeks. In the present study, full completion at base-
line by 82.9% of participants indicates that it is accept-
able also to people at the start of a trial, in which some
form of anti-HIV treatment was being used before the
trial began. Distributions of the HIVTSQc item scores
were also negatively skewed. Thus, the majority of
patients found their treatment more satisfactory at
Week 48 than at baseline. Nevertheless, some found
their trial treatment less satisfactory in certain respects,
indicated by negative item scores on the scale +3 to
−3. Possibly, before the trial, some patients were not
monitored as closely, nor were they given such strict
instructions about medication-taking as they were for
the trial. This may in part explain why the trial treat-
ments were seen by some as presenting more demands,
being less ﬂexible, and interfering more with lifestyle,
so they might not recommend them to others as much
as they did the pretrial treatments.
The completion rate was very good for both meas-
ures. It is not known why some people did not com-
plete the measures at all, but their demographic
characteristics were similar to those of the whole sam-
ple, suggesting that noncompletion may have been
driven by study staff, rather than patient characteris-
tics. Interestingly, among those actually attempting the
HIVTSQs, African American people were less likely to
complete it in full.
In determining the structure of the HIVTSQs and
HIVTSQc, the HIVTSQs 10-item treatment satisfac-
tion scale was strongly supported (baseline scale
alpha = 0.89; Week 48 scale alpha = 0.91) as was the
HIVTSQc 10-item treatment satisfaction change scale
(Week 48 scale alpha = 0.92). These alphas were even
higher than found for the nine-item scale in the origi-
nal validation of the status version [1] (Week 8 or 16
alpha = 0.82 in full sample of Americans and Canadi-
ans; alpha = 0.80 in US data). Moreover, the subscales
for both the HIVTSQs and HIVTSQc had
alpha > 0.80, at baseline and Week 48, again higher
than in the original study (general satisfaction/clinical
alpha = 0.80 in the United States/Canada, 0.77 in the
United States alone; lifestyle/ease alpha = 0.74 in the
United States/Canada; 0.75 in the United States alone).
The weakest item generally, as demonstrated by stand-
ardized regression weights and Cronbach’s alpha,
concerned “understanding of your HIV.” It may be
necessary to change the wording of this item in future,
possibly to focus on “understanding of your treat-
ment,” as included in our two recently developed
measures of treatment satisfaction in pediatric diabe-
tes, for completion by parents and by teenagers (the
DTSQ-Parent and DTSQ-Teen).
Within the HIVTSQs, the revised demands item
was the strongest item in the treatment satisfaction
scale. Because of the high internal consistency reliabil-
ity of both the treatment satisfaction scale and the
treatment satisfaction change scale, up to ﬁve items
may be missed from the scale, while still computing the
scale score. The subscales can each be computed when
only one item is missed. This method of computing
missing values assumes that items are missed at ran-
dom and that they all measure a single underlying
latent construct. In some trials using the earlier version
of the HIVTSQs, the nine-item total treatment satis-
faction scores (ranging 0–54) were converted to per-
centages (0–100) (Jordan et al.) [8]. The same could be
done with the 10-item total treatment satisfaction
scores (0–60), at the discretion of those using the
measure. While this facilitates interpretation, it tends
to inﬂate any apparent differences between patient
groups. A greater apparent inﬂation would result from
changing HIVTSQs subscale scores (range 0–30) into
percentages and when translating HIVTSQc scale
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scores (−30 through zero to +30) or subscale scores
(−15 through zero to +15) to percentage differences
from zero (−100% to +100% satisfaction). The
skewed distribution of scale and subscale scores, par-
ticularly those from the change version, indicates that
nonparametric statistics may be appropriate. Alterna-
tively, ranked data may be used, or measures can be
taken to normalize the skew before analysis using par-
ametric methods. With large sample sizes, there may
be very little difference between the results of nonpar-
ametric and parametric analyses, but it is advisable to
check. Two years between baseline and follow-up is a
long time for people to make HIVTSQc change judg-
ments. The fact that HIVTSQc item change scores all
correlated positively with the difference between status
scores obtained at baseline and Week 48 provides
some evidence that meaningful judgments were being
made, though the HIVTSQc might best be adminis-
tered after a shorter time period (6 or 12 months into
a trial) to enable respondents to recall more clearly
their experience of the previous treatment.
Some degree of construct validity has already been
established for the HIVTSQs, by comparing treat-
ments with more/less complex regimens [1]. The
present study conﬁrmed a relationship between viral
load and control item scores, in both the status and
change measures, and a relationship between the gen-
eral satisfaction/clinical subscale and viral load at
Week 48. In contrast, the lifestyle/ease subscale did not
correlate with viral load at the same time point, indi-
cating that the two subscales may be useful in discrim-
inating between treatments with similar effects on
clinical status, but easier/more difﬁcult to take. Inter-
estingly, the scale scores were not correlated with viral
load, or viral load change. Thus, overall satisfaction
is not simply a matter of controlling clinical status.
Indeed, if viral load and satisfaction correlated
strongly, there would be no need to measure satisfac-
tion with treatment. Patients’ perceptions, including
convenience, and their understanding of test results
can also inﬂuence satisfaction levels.
Ethnicity, Viral Load, and Treatment Satisfaction
If HIVTSQs general satisfaction/clinical, lifestyle/ease,
and treatment satisfaction scores were directly related
to clinical status, it would be expected that African
Americans in this trial would be less satisﬁed than
Caucasians, because their HIV status was somewhat
worse. The counterintuitive ﬁnding, that African
American people reported greater baseline satisfaction
on both the subscales and the total scale, indicates that
the observed ethnic group difference may be cultural
rather than a reﬂection of different levels of disease
progression. Greater treatment satisfaction among
non-Caucasians was found in the earlier HIVTSQ val-
idation [1] and contrasts with studies in which non-
Caucasians tend to be either less satisﬁed with medical
care than Caucasians [13,14] (1996 data [15]), or
equally satisﬁed [14,16] (2000 data). The prevalence
of non-Caucasian and particularly African American
people among those attending their Week 48 appoint-
ment yet missing HIVTSQc items is notable, especially
because African American people tended to report
greater baseline satisfaction on the HIVTSQs. It is
important to use the recommendations for dealing
with missing values to compute subscale and scale
scores for as many people as possible without damage
to reliability at follow-up points, when dropouts or
missing data can undermine randomization.
The correlation between viral load and HIVTSQs
scores in the original study [1] was r = −0.28 with
treatment satisfaction and r = −0.33 with the control
item (both small but highly signiﬁcant). Those patients
were recruited with plasma viral load at least 400
HIV-1 RNA copies/ml and their baseline mean viral
load was 4.10 HIV-1 RNA copies/ml(log10) (SD 0.76).
By the week of HIVTSQ completion (Week 8 or 16),
however, their mean viral load was down to 3.10 (SD
0.85). Baseline mean viral load in the present study,
transformed to a log10 scale, was 4.09 (SD 0.82).
Thus, the viral load at the start of the two trials was
very similar. At baseline of the present study, however,
neither the treatment satisfaction scale score nor the
control item score correlated signiﬁcantly with base-
line viral load. There are two possible reasons for this
difference between the two studies. In the earlier
study, which collected data 8 or 16 weeks into the
trial, patients would by that time be familiar with viral
load reporting and might have based their perceptions
of HIV control on those readings; also, the trial pro-
tocol of the earlier study did not dictate when to
administer the HIVTSQs in relation to viral load
reporting and some patients may have known their
results before completing the questionnaire. In the
present study, however, all patients completed the
HIVTSQs before receiving their test results and so a
weaker correlation between HIVTSQs scores and viral
load might be expected. Patients would rely on their
perceptions of HIV control, which would be hard,
particularly for asymptomatic patients. Viral load
spanned a large range and may have included sympto-
matic as well as relatively symptom-free patients. Cor-
relations between HIVTSQs control item scores and
viral load at baseline and Week 48 support the sugges-
tion that participation in the trial increased under-
standing of viral load results, which affected ratings of
the control item. They also suggest that African Amer-
ican and particularly Hispanic participants had less
information about their viral loads at baseline, possi-
bly diluting the association between viral load and
control item responses in the full sample. The correla-
tion was signiﬁcant among Caucasian participants at
baseline and became signiﬁcant in the combined sam-
ple by Week 48.
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For the HIVTSQc, there was no ethnic difference
in subscale or scale scores, but the means indicated a
tendency for African Americans to indicate the great-
est improvement in satisfaction. Correlations showed
that particularly Caucasian and, to a lesser extent,
African American respondents whose viral load had
improved more by the close of the trial reported a
greater increase in satisfaction on the HIVTSQc con-
trol(c) item. Despite a tendency for a similar relation-
ship between total treatment satisfaction change and
viral load change, the negative correlation was not
signiﬁcant and the correlation with the subscale
scores was small in each case. The stronger correla-
tion with control(c) is to be expected, because this is
the one item out of the 10 that is likely to relate
directly to viral load and physical outcomes. This
association provides preliminary evidence of construct
validity of the HIVTSQc. The stronger correlation
between viral load change and HIVTSQc control(c)
scores for Caucasian patients compared with African
American or Hispanic patients suggests again that
Caucasian participants might have had more informa-
tion about their viral load and used this when
responding to the control(c) item. This ﬁnding has
implications for the education of people infected with
HIV, but requires further investigation because of the
small number of Hispanic patients in the present
study.
Because of the complex relationships identiﬁed
between ethnicity, understanding of viral load results,
and perceptions of HIV control, ethnicity could use-
fully be included as a potential confounding variable
(covariate) in trial analyses of HIVTSQs and HIVT-
SQc data. This is in addition to ensuring that ethnic
groups are similarly represented in each treatment
group at recruitment, because African Americans
may also be rather more likely than other Americans
to miss items. If a scale score cannot be computed for
them at any point during the trial, as a result of miss-
ing several items, this could potentially exclude
patients indicating higher satisfaction levels from trial
analyses. It is also advisable to include baseline
HIVTSQs scores as a covariate to deal with any
potential confounding inﬂuence on HIVTSQc scores
later in the trial. The less satisﬁed people are when
they begin the trial, the more room there will be for
improvement.
These two measures are already available in several
languages, produced using two independent forward
translations, reconciliation, and two back translations,
with revision and further back translation as needed.
Further work will include assessment of the equiva-
lence of completion methods, such as pen and paper
compared with telephone administration, further lin-
guistic validation of translations, including full cogni-
tive debrieﬁng with patients, as well as analysis of
sensitivity to differences between treatments.
Conclusion
The HIVTSQs and HIVTSQc each has a structure with
two ﬁve-item subscales, measuring general satisfac-
tion/clinical and lifestyle/ease satisfaction. A 10-item
treatment satisfaction scale may also be computed for
each measure. The HIVTSQs subscale and scale scores
can be used at baseline and later in the trial to make
comparisons between groups and over time. The
HIVTSQc subscale and scale scores allow an improve-
ment to be expressed later in the trial, even by patients
with high levels of satisfaction at baseline. The sub-
scales and scales in both measures have very good
internal consistency reliability. The control item score
from each measure correlates with viral load more
strongly than does the scale score, and this relationship
becomes stronger during a trial, suggesting that under-
standing of viral load results may improve during a
trial. Together, the HIVTSQs and HIVTSQc can be
used in trials of new HIV treatments, to provide insight
into patients’ perspectives, which are not as closely
related to viral load as might be expected.
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